SS
AVDL

Simplicity Solutions’s Avadel Pharmaceuticals AVDL Stock Holding History

Simplicity Solutions’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,000
Closed -$91.6K – 1068
2023
Q1 		$91.6K Buy
+10,000
New +$82.2K ﹤0.01% 1069

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Simplicity Solutions's AVDL Position: Q2 2023 in Review

Simplicity Solutions sold out of Avadel Pharmaceuticals (AVDL) in Q2 2023, closing a stake of 10,000 shares — an estimated $91.6K sold.

Simplicity Solutions first reported a position in AVDL in Q1 2023 and held it in 1 quarter. The position peaked at $91.6K in Q1 2023. 101 funds tracked by Wall St. Rank hold AVDL as of Q2 2023.

  • Simplicity Solutions reported no remaining Avadel Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Simplicity Solutions sold 10,000 Avadel Pharmaceuticals shares in Q2 2023, an estimated $91.6K.
  • Simplicity Solutions first reported a position in Avadel Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Simplicity Solutions's Avadel Pharmaceuticals position peaked at $91.6K in Q1 2023.
  • 101 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2023.

Based on Simplicity Solutions's 13F filing for Q2 2023, filed 26 Jul 2023.